Clinical Trial

Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study

Study acronym: RITE
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 14, 2017 (before its estimated December 2018 completion). Its status may not reflect the trial's current state.
Summary
Reslizumab is a type of medicine called a monoclonal antibody that is made in the research clinic; it works by blocking a specific protein in the body called interleukin-5. The study medicine, reslizumab, is not yet approved for doctors to treat patients with EGPA. It is considered an experimental drug in this study.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2016-10-26; most recent amendment 2026-06-15.
Status change: Recruiting → Completed 2026-04-14
Status change: Not Yet Recruiting → Recruiting 2017-09-12
Trial Details
NCT Number NCT02947945
Lead Sponsor National Jewish Health
Collaborators: Teva Pharmaceuticals USA
Conditions Asthma
Enrollment 10 participants
Start Date 2017-09-12
Primary Completion 2018-12 (estimated)
Study Completion 2018-12 (estimated)
Updated on ClinicalTrials.gov 2017-09-14